XML 17 R48.htm IDEA: XBRL DOCUMENT v2.4.0.6
Quarterly Financial Information (Unaudited) (Details) (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 12 Months Ended
Jun. 30, 2012
Mar. 31, 2012
Dec. 31, 2011
Sep. 30, 2011
Jun. 30, 2011
Mar. 31, 2011
Dec. 31, 2010
Sep. 30, 2010
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2010
Revenues:                      
Research and development support $ 1,184 $ 1,320 $ 945 $ 1,068 $ 1,566 $ 2,190 $ 2,005 $ 1,495 $ 4,517 $ 7,256 $ 5,365
License and milestone fees 950 999 6,025 1,187 2,859 858 866 1,810 9,161 6,393 5,698
Clinical materials revenue 818 933 647 281 2,080 2,163 1,307 106 2,679 5,656 2,880
Total revenues 2,952 3,252 7,617 2,536 6,505 5,211 4,178 3,411 16,357 19,305 13,943
Expenses:                      
Research and development 19,539 16,933 15,559 17,161 18,261 15,763 16,004 13,425 69,192 63,453 50,280
General and administrative 5,726 5,021 4,834 4,841 4,438 4,550 3,688 3,364 20,422 16,040 14,898
Total operating expenses 25,265 21,954 20,393 22,002 22,699 20,313 19,692 16,789 89,614 79,493 65,178
Loss from operations (22,313) (18,702) (12,776) (19,466) (16,194) (15,102) (15,514) (13,378) (73,257) (60,188) (51,235)
Other (expense) income, net (101) 33 23 (17) 44 99 1,281 490      
Loss before benefit for income taxes (22,414) (18,669) (12,753) (19,483) (16,150) (15,003) (14,233) (12,888) (73,319) (58,274) (51,177)
Net loss $ (22,414) $ (18,669) $ (12,753) $ (19,483) $ (16,150) $ (15,003) $ (14,233) $ (12,888) $ (73,319) $ (58,274) $ (50,912)
Basic and diluted net loss per common share (in dollars per share) $ (0.29) $ (0.24) $ (0.17) $ (0.26) $ (0.23) $ (0.22) $ (0.21) $ (0.19) $ (0.95) $ (0.85) $ (0.87)